{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:28:01Z","timestamp":1774880881688,"version":"3.50.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>IncobotulinumtoxinA is an effective neuromodulator for treating glabellar rhytids. The relationship between dose and reduction in rhytid severity is well established. However, the effects of escalating doses on the treatment duration response are less understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to assess the effects of increasing doses of incobotulinumtoxinA on the treatment duration for glabellar rhytids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A randomized, double-blind, Phase IV study was conducted at a fully accredited, outpatient surgical facility. Subjects (31 female, 7 male) with moderate to severe glabellar rhytids were randomized to 1 of 3 incobotulinumtoxinA dose groups: 20, 60, or 100 U. Effect duration was determined by calculating the time to return to baseline for dynamic glabellar lines during maximal contraction. Follow-up was completed through 1 year, and adverse events were monitored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median duration of effect was 120 days (95% confidence interval [CI] [90, 180 days]), 180 days (95% CI [180, 210 days]), and 270 days (95% CI [240, 330 days]) for the 20-, 60-, and 100-U groups, respectively. A Wald chi-square test from the Cox regression on the primary efficacy variable indicated a statistically significant effect of dose group on time to baseline (chi square\u2005=\u200554.63; df\u2005=\u20052; P\u2005&amp;lt;\u20050.001). Hazard ratios were HR\u2005=\u20050.21 (95% CI [0.10; 0.43] for the 60-U vs the 20-U group, and HR\u2005=\u20050.06 (95% CI [0.10; 0.43]) for the 100-U vs the 20-U group, indicating a statistically longer return to baseline for both the 60- and 100-U cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is a dose-dependent relationship between incobotulinumtoxinA and duration of effect in the glabella.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 2<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjaa220","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T19:53:10Z","timestamp":1595965990000},"page":"NP500-NP511","source":"Crossref","is-referenced-by-count":13,"title":["A Double-Blind, Randomized Clinical Trial to Determine Effects of Increasing Doses and Dose-Response Relationship of IncobotulinumtoxinA in the Treatment of Glabellar Rhytids"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-6029","authenticated-orcid":false,"given":"Marc A","family":"Polacco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam E","family":"Singleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian H","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conner","family":"Maas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey S","family":"Maas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"2022113023045744000_CIT0001","author":"The Aesthetic Society\u2019s","year":"2014"},{"key":"2022113023045744000_CIT0002","first-page":"1","article-title":"The American Society","volume":"39","year":"2019","journal-title":"Aesthet Surg J."},{"key":"2022113023045744000_CIT0003","author":"American Academy of Facial Plastic and Reconstructive Surgery.","year":"2009"},{"issue":"5","key":"2022113023045744000_CIT0004","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00000637-199711000-00002","article-title":"Local injection into mimetic muscles of botulinum toxin A for the treatment of facial lines","volume":"39","author":"Guerrissi","year":"1997","journal-title":"Ann Plast Surg."},{"issue":"1","key":"2022113023045744000_CIT0005","first-page":"41","article-title":"Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring","volume":"32","author":"Avci","year":"2013","journal-title":"Semin Cutan Med Surg."},{"issue":"2","key":"2022113023045744000_CIT0006","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00006534-199902000-00055","article-title":"Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery","volume":"103","author":"Fagien","year":"1999","journal-title":"Plast Reconstr Surg."},{"issue":"4","key":"2022113023045744000_CIT0007","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0161-6420(96)30644-1","article-title":"The use of botulinum A toxin to ameliorate facial kinetic frown lines","volume":"103","author":"Foster","year":"1996","journal-title":"Ophthalmology."},{"issue":"1","key":"2022113023045744000_CIT0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1524-4725.1992.tb03295.x","article-title":"Treatment of glabellar frown lines with C. botulinum-A exotoxin","volume":"18","author":"Carruthers","year":"1992","journal-title":"J Dermatol Surg Oncol."},{"key":"2022113023045744000_CIT0009","author":"Allergan Inc.","year":"2018"},{"key":"2022113023045744000_CIT0010","year":"2019"},{"issue":"2","key":"2022113023045744000_CIT0011","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"J Clin Aesthet Dermatol."},{"key":"2022113023045744000_CIT0012","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1097\/DSS.0000000000001920","article-title":"Efficacy and safety of prabotulinum A and onabotulinum A for crow\u2019s feet: a phase 3, multicenter, randomized, double-blind, split-face study","volume":"45","author":"Cheon","year":"2019","journal-title":"Dermatol Surg"},{"key":"2022113023045744000_CIT0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2009.02879.x","article-title":"Xeomin: an innovative new botulinum toxin type A","volume":"16 Suppl 2","author":"Frevert","year":"2009","journal-title":"Eur J Neurol."},{"issue":"5","key":"2022113023045744000_CIT0014","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","article-title":"Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia","volume":"67","author":"Jost","year":"2007","journal-title":"Drugs."},{"issue":"5","key":"2022113023045744000_CIT0015","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.toxicon.2009.03.010","article-title":"Xeomin is free from complexing proteins","volume":"54","author":"Frevert","year":"2009","journal-title":"Toxicon."},{"key":"2022113023045744000_CIT0016","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1111\/j.1524-4725.2010.01706.x","article-title":"Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines","volume":"36 Suppl 4","author":"Sattler","year":"2010","journal-title":"Dermatol Surg."},{"key":"2022113023045744000_CIT0017","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","article-title":"Routine use of Xeomin in patients previously treated with Botox: long term results","volume":"16 Suppl 2","author":"Dressler","year":"2009","journal-title":"Eur J Neurol."},{"key":"2022113023045744000_CIT0018","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-1331.2009.02880.x","article-title":"Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm","volume":"16 Suppl 2","author":"Jankovic","year":"2009","journal-title":"Eur J Neurol."},{"issue":"2","key":"2022113023045744000_CIT0019","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00702-014-1252-9","article-title":"Safety aspects of incobotulinumtoxinA high-dose therapy","volume":"122","author":"Dressler","year":"2015","journal-title":"J Neural Transm"},{"issue":"6","key":"2022113023045744000_CIT0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"2 Spec No","key":"2022113023045744000_CIT0021","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1524-4725.2011.02248.x","article-title":"Validated assessment scales for the upper face","volume":"38","author":"Flynn","year":"2012","journal-title":"Dermatol Surg."},{"key":"2022113023045744000_CIT0022","volume-title":"Xeomin: Medicatio","author":"Merz Pharma GmbH & Co KGaA","year":"2010"},{"issue":"5","key":"2022113023045744000_CIT0023","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/14764172.2010.514920","article-title":"A validated facial grading scale: the future of facial ageing measurement tools?","volume":"12","author":"Carruthers","year":"2010","journal-title":"J Cosmet Laser Ther."},{"key":"2022113023045744000_CIT0024","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/archotol.124.12.1315","article-title":"Glabellar anatomy: the anatomic basis for BoTox therapy","volume":"124","author":"MacDonald","year":"1998","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"4","key":"2022113023045744000_CIT0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1064-7406(03)00090-7","article-title":"Relevant anatomy for botulinum toxin facial rejuvenation","volume":"11","author":"Loos","year":"2003","journal-title":"Facial Plast Surg Clin North Am."},{"key":"2022113023045744000_CIT0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","article-title":"A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience","volume":"17","author":"Negro","year":"2015","journal-title":"J Headache Pain."},{"issue":"3","key":"2022113023045744000_CIT0027","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archfaci.2011.1142","article-title":"Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA","volume":"14","author":"Yu","year":"2012","journal-title":"Arch Facial Plast Surg."},{"issue":"5","key":"2022113023045744000_CIT0028","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00266-008-9199-6","article-title":"A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects","volume":"32","author":"Harii","year":"2008","journal-title":"Aesthetic Plast Surg."},{"issue":"5","key":"2022113023045744000_CIT0029","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/PRS.0b013e3181b5641b","article-title":"Evaluation of variable-dose treatment with a new US botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study","volume":"124","author":"Kane","year":"2009","journal-title":"Plast Reconstr Surg."},{"issue":"2","key":"2022113023045744000_CIT0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.WNF.0000240951.18821.50","article-title":"Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins","volume":"30","author":"Wohlfarth","year":"2007","journal-title":"Clin Neuropharmacol."},{"issue":"10","key":"2022113023045744000_CIT0031","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1524-4725.2011.02075.x","article-title":"Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A","volume":"37","author":"Schlessinger","year":"2011","journal-title":"Dermatol Surg."},{"issue":"2","key":"2022113023045744000_CIT0032","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00403-011-1179-z","article-title":"Comparison of the spread of three botulinum toxin type A preparations","volume":"304","author":"Kerscher","year":"2012","journal-title":"Arch Dermatol Res."},{"issue":"4","key":"2022113023045744000_CIT0033","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","article-title":"Studies on the dissociation of botulinum neurotoxin type A complexes","volume":"57","author":"Eisele","year":"2011","journal-title":"Toxicon."},{"issue":"1","key":"2022113023045744000_CIT0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","article-title":"Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products","volume":"15","author":"Frevert","year":"2015","journal-title":"Drugs R D."},{"issue":"4","key":"2022113023045744000_CIT0035","article-title":"Incobotulinumtoxina","volume":"2","author":"Mastromauro","year":"2015","journal-title":"Int J Neurorehabilitation Eng"},{"issue":"13","key":"2022113023045744000_CIT0036","first-page":"3110","article-title":"Comparing dose and duration of onabotulinumtoxinA and incobotulinumtoxinA in blepharospasm and hemifacial spasm","volume":"55","author":"Giacometti","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"2022113023045744000_CIT0037","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13555-013-0033-y","article-title":"Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxinA and onabotulinumtoxinA for the treatment of facial rhytids","volume":"3","author":"Kassir","year":"2013","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6190","key":"2022113023045744000_CIT0038","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1126\/science.1253823","article-title":"Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex","volume":"344","author":"Lee","year":"2014","journal-title":"Science."},{"issue":"4","key":"2022113023045744000_CIT0039","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1083\/jcb.200910119","article-title":"Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin","volume":"189","author":"Sugawara","year":"2010","journal-title":"J Cell Biol."},{"issue":"2","key":"2022113023045744000_CIT0040","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbrc.2005.04.007","article-title":"Clostridium botulinum type A progenitor toxin binds to Intestine-407 cells via N-acetyllactosamine moiety","volume":"331","author":"Kojima","year":"2005","journal-title":"Biochem Biophys Res Commun."},{"issue":"49","key":"2022113023045744000_CIT0041","doi-asserted-by":"crossref","first-page":"35617","DOI":"10.1074\/jbc.M113.521179","article-title":"Crystal structure of Clostridium botulinum whole hemagglutinin reveals a huge triskelion-shaped molecular complex","volume":"288","author":"Amatsu","year":"2013","journal-title":"J Biol Chem."},{"issue":"4","key":"2022113023045744000_CIT0042","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/17425255.2016.1152262","article-title":"Pharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity","volume":"12","author":"Zeuner","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"2022113023045744000_CIT0043","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.3390\/toxins8010004","article-title":"Efficacy and safety of a new botulinum toxin type A free of complexing proteins","volume":"8","author":"Oh","year":"2015","journal-title":"Toxins (Basel)"},{"key":"2022113023045744000_CIT0044","first-page":"1","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"key":"2022113023045744000_CIT0045","first-page":"411","article-title":"Diffusion of botulinum toxins","volume":"2","author":"Brodsky","year":"2012","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"2022113023045744000_CIT0046","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenkamper","year":"2006","journal-title":"J Neural Transm"},{"issue":"3","key":"2022113023045744000_CIT0047","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/mus.21343","article-title":"Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg","volume":"40","author":"Carli","year":"2009","journal-title":"Muscle Nerve."},{"key":"2022113023045744000_CIT0048","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00702-004-0234-8","article-title":"Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) comparted with commercially available botulinum toxin type A (BOTOX) in healthy volunteers","volume":"112","author":"Jost","year":"2005","journal-title":"J Neural Transm"},{"issue":"6","key":"2022113023045744000_CIT0049","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jocd.12949","article-title":"Two different types of botulinum toxins: is there a difference in efficacy and longevity?","volume":"18","author":"Shome","year":"2019","journal-title":"J Cosmet Dermatol."},{"key":"2022113023045744000_CIT0050","author":"American Society for Dermatologic Surgery.","year":"2017"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjaa220\/33539722\/sjaa220.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/41\/6\/NP500\/47468746\/sjaa220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/41\/6\/NP500\/47468746\/sjaa220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T23:29:34Z","timestamp":1669850974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/41\/6\/NP500\/5877420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,7,28]]},"published-print":{"date-parts":[[2021,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjaa220","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,7,28]]}}}